Cortexyme has completed its merger with Novosteo, a biopharmaceutical company that develops drugs for rare skeletal diseases and bone cancer. Novosteo shareholders received 15.5% of the combined company, which will change its name to Quince Therapeutics in the coming months. Cortexyme also granted the transferred employees from Novosteo stock options of 3,744,255 shares at the close of business on May 23, 2022.